Comparison of DPP4 inhibitors versus luseogliflozin, a SGLT2 inhibitor using cotinuous glucose monitoring (CGM)

Comparison of DPP4 inhibitors versus luseogliflozin, a SGLT2 inhibitor using cotinuous glucose monitoring (CGM) - Comparison of DPP4 inhibitors versus luseogliflozin, a SGLT2 inhibitor using cotinuous glucose monitoring (CGM)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000014333

Enrollment

Registered

2014-07-14

Start date

2014-07-14

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes

Interventions

Luseogliflozin DPP4 inhibitors

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: type 2 diabetes using DPP4 inhibitors

Exclusion criteria

Exclusion criteria: liver or renal dysfunction

Design outcomes

Primary

Measure	Time frame
CGM(BS average, SD, MAGE, M-value, AUC)	—

Countries

Japan

Contacts

Public ContactNobutoshi Fushimi

Ichinomiyanishi hospital Department of Endocrinology and Diabetes

nobutoshi243@yahoo.co.jp0586-48-0077

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026